SML1651
Iloprost
≥98% (HPLC)
别名:
(E)-(3aS, 4R, 5R, 6aS)-Hexahydro-5-hydroxy-4-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-Δ2(1H),Δ-pentalenevaleric acid, Cilaprost, ZK 36374; (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C22H32O4
CAS号:
分子量:
360.49
MDL编号:
UNSPSC代码:
51111800
PubChem化学物质编号:
NACRES:
NA.77
质量水平
检测方案
≥98% (HPLC)
形式
film
储存条件
desiccated
颜色
colorless
溶解性
DMSO: 10 mg/mL, clear
储存温度
−20°C
SMILES字符串
[H][C@@]12[C@@](C/C(C2)=C/CCCC(O)=O)([H])[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C1
InChI
1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18?,19-,20+,21+/m0/s1
InChI key
HIFJCPQKFCZDDL-SGSAMSKHSA-N
生化/生理作用
Iloprost is a potent prostacyclin PGI2 analog that binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost acts as a vasodilator and antihypertensive, and inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. Iloprost dilates systemic and pulmonary arterial vascular beds and has been used clinically for pulmonary arterial hypertension (PAH), scleroderma, and Raynaud′s syndrome.
Iloprost is used to treat children with PH (pulmonary hypertension) after the surgery to clear CHD (congenital heart disease). In transplant patients, this prostacyclin analogue is used to inhibit renal dysfunction. Iloprost performs various functions like vasodilatation and cytoprotection. It has higher stability than prostacyclin.
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
A review of the use of iloprost, a synthetic prostacyclin, in the prevention of radiocontrast nephropathy in patients undergoing coronary angiography and intervention.
Kassis HM, et al.
Clinical Cardiology, 38(8), 492-498 (2015)
Meyler's Side Effects of Endocrine and Metabolic Drugs (2009)
Iloprost for children with pulmonary hypertension after surgery to correct congenital heart disease.
Xu Z, et al.
Pediatric Pulmonology, 50(6), 588-595 (2015)
Joseph Castillo et al.
Cancer research, 79(15), 3916-3927 (2019-06-12)
Regulatory T cells (Treg) are immunosuppressive and negatively impact response to cancer immunotherapies. CREB-binding protein (CBP) and p300 are closely related acetyltransferases and transcriptional coactivators. Here, we evaluate the mechanisms by which CBP/p300 regulate Treg differentiation and the consequences of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门